BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003;134:1057-1063; discussion 1063-1065. [PMID: 14668741 DOI: 10.1016/j.surg.2003.07.025] [Cited by in Crossref: 184] [Cited by in F6Publishing: 156] [Article Influence: 10.8] [Reference Citation Analysis]
Number Citing Articles
1 Franko J, Feng W, Yip L, Genovese E, Moser AJ. Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients. J Gastrointest Surg. 2010;14:541-548. [PMID: 19997980 DOI: 10.1007/s11605-009-1115-0] [Cited by in Crossref: 171] [Cited by in F6Publishing: 150] [Article Influence: 14.3] [Reference Citation Analysis]
2 DeLuzio MR, Barbieri AL, Israel G, Emre S. Two Cases of Primary Hepatic Neuroendocrine Tumors and a Review of the Current Literature. Ann Hepatol. 2017;16:621-629. [PMID: 28611270 DOI: 10.5604/01.3001.0010.0313] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
3 Maxwell JE, Sherman SK, O'Dorisio TM, Bellizzi AM, Howe JR. Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy? Surgery. 2016;159:320-333. [PMID: 26454679 DOI: 10.1016/j.surg.2015.05.040] [Cited by in Crossref: 86] [Cited by in F6Publishing: 69] [Article Influence: 14.3] [Reference Citation Analysis]
4 Nomura N, Fujii T, Kanazumi N, Takeda S, Nomoto S, Kasuya H, Sugimoto H, Yamada S, Nakao A. Nonfunctioning neuroendocrine pancreatic tumors: our experience and management. J Hepatobiliary Pancreat Surg 2009;16:639-47. [PMID: 19365596 DOI: 10.1007/s00534-009-0099-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
5 Maire F, Lombard-bohas C, O’toole D, Vullierme M, Rebours V, Couvelard A, Pelletier AL, Zappa M, Pilleul F, Hentic O, Hammel P, Ruszniewski P. Hepatic Arterial Embolization versus Chemoembolization in the Treatment of Liver Metastases from Well-Differentiated Midgut Endocrine Tumors: A Prospective Randomized Study. Neuroendocrinology 2012;96:294-300. [DOI: 10.1159/000336941] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 5.7] [Reference Citation Analysis]
6 Krampitz GW, Norton JA, Poultsides GA, Visser BC, Sun L, Jensen RT. Lymph nodes and survival in pancreatic neuroendocrine tumors. Arch Surg. 2012;147:820-827. [PMID: 22987171 DOI: 10.1001/archsurg.2012.1261] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 8.1] [Reference Citation Analysis]
7 House MG, Cameron JL, Lillemoe KD, Schulick RD, Choti MA, Hansel DE, Hruban RH, Maitra A, Yeo CJ. Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg. 2006;10:138-145. [PMID: 16368504 DOI: 10.1016/j.gassur.2005.05.004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 3.7] [Reference Citation Analysis]
8 Abutaka A, El-Matbouly M, Helmy I, Elmoghazy W, Sulieman I, Ben Gashir M, Soofi M, Khalaf H, Elaffandi A. Repeat liver resection for pure large cell neuroendocrine carcinoma of the gallbladder: a favorable outcome. World J Surg Oncol 2019;17:126. [PMID: 31325969 DOI: 10.1186/s12957-019-1666-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Partelli S, Maurizi A, Tamburrino D, Baldoni A, Polenta V, Crippa S, Falconi M. GEP-NETS update: a review on surgery of gastro-entero-pancreatic neuroendocrine tumors. Eur J Endocrinol. 2014;171:R153-R162. [PMID: 24920289 DOI: 10.1530/eje-14-0173] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
10 Akerström G, Hellman P. Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007;21:87-109. [PMID: 17382267 DOI: 10.1016/j.beem.2006.12.004] [Cited by in Crossref: 110] [Cited by in F6Publishing: 83] [Article Influence: 7.9] [Reference Citation Analysis]
11 Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore). 2004;83:43-83. [PMID: 14747767 DOI: 10.1097/01.md.0000112297.72510.32] [Cited by in Crossref: 213] [Cited by in F6Publishing: 172] [Article Influence: 12.5] [Reference Citation Analysis]
12 Ruiz-Tovar J, Priego P, Martínez-Molina E, Morales V, Sanjuanbenito A, Lobo E. Pancreatic neuroendocrine tumours. Clin Transl Oncol 2008;10:493-7. [PMID: 18667380 DOI: 10.1007/s12094-008-0238-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
13 Xiang JX, Zhang XF, Weiss M, Aldrighetti L, Poultsides GA, Bauer TW, Fields RC, Maithel SK, Marques HP, Pawlik TM. Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome. J Surg Oncol 2018;118:1096-104. [PMID: 30261105 DOI: 10.1002/jso.25246] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Valadares LJ, Costa Junior W, Ribeiro HS, Diniz AL, Coimbra FJ, Herman P. Resection of liver metastasis from neuroendocrine tumors: evaluation of results and prognostic factors. Rev Col Bras Cir. 2015;42:25-31. [PMID: 25992697 DOI: 10.1590/0100-69912015001006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
15 Tomassetti P, Campana D, Piscitelli L, Casadei R, Santini D, Nori F, Morselli-Labate AM, Pezzilli R, Corinaldesi R. Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol 2005;16:1806-10. [PMID: 16085691 DOI: 10.1093/annonc/mdi358] [Cited by in Crossref: 139] [Cited by in F6Publishing: 127] [Article Influence: 8.7] [Reference Citation Analysis]
16 Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, Pitt HA. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241:776-783; discussion 783-785. [PMID: 15849513 DOI: 10.1097/01.sla.0000161981.58631.ab] [Cited by in Crossref: 250] [Cited by in F6Publishing: 213] [Article Influence: 15.6] [Reference Citation Analysis]
17 Cano-Valderrama O, Díez-Valladares L, Domínguez-Serrano I, Cerdán-Santacruz C, Torres-García AJ. [Prolonged survival after resection of liver metastasis of a pancreatic neuroendocrine tumour]. Cir Esp 2011;89:322-3. [PMID: 21296341 DOI: 10.1016/j.ciresp.2010.04.011] [Reference Citation Analysis]
18 Pasieka JL, McEwan AJ, Rorstad O. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. Surgery. 2004;136:1218-1226. [PMID: 15657579 DOI: 10.1016/j.surg.2004.06.050] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 3.2] [Reference Citation Analysis]
19 Hines OJ, Reber HA. Pancreatic neoplasms. Curr Opin Gastroenterol. 2004;20:452-458. [PMID: 15689678 DOI: 10.1097/00001574-200409000-00006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
20 Bendelow J, Apps E, Jones L, Poston G. Carcinoid syndrome. European Journal of Surgical Oncology (EJSO) 2008;34:289-96. [DOI: 10.1016/j.ejso.2007.07.202] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
21 Frilling A, Weber F, Cicinnati V, Broelsch C. Role of radiolabeled octreotide therapy in patients with metastatic neuroendocrine neoplasms. Expert Rev Endocrinol Metab 2007;2:517-27. [PMID: 30290419 DOI: 10.1586/17446651.2.4.517] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Buicko JL, Finnerty BM, Zhang T, Kim BJ, Fahey TJ, Nancy Du YC. Insights into the biology and treatment strategies of pancreatic neuroendocrine tumors. Ann Pancreat Cancer. 2019;2. [PMID: 31535089 DOI: 10.21037/apc.2019.06.02] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
23 Saxena A, Chua TC, Perera M, Chu F, Morris DL. Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. Surg Oncol 2012;21:e131-41. [PMID: 22658833 DOI: 10.1016/j.suronc.2012.05.001] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 8.1] [Reference Citation Analysis]
24 Tsutsumi K, Ohtsuka T, Fujino M, Nakashima H, Aishima S, Ueda J, Takahata S, Nakamura M, Oda Y, Tanaka M. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification. J Hepatobiliary Pancreat Sci 2014;21:418-25. [DOI: 10.1002/jhbp.47] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
25 Sethi S, Kulkarni P. A rare case of a primary hepatic neuroendocrine tumor. Transl Gastroenterol Hepatol. 2016;1:66. [PMID: 28138632 DOI: 10.21037/tgh.2016.06.07] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
26 Teh SH, Deveney C, Sheppard BC. Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable? Am J Surg. 2007;193:610-63; discussion 613. [PMID: 17434366 DOI: 10.1016/j.amjsurg.2007.01.014] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
27 Li J, Luo G, Fu D, Jin C, Hao S, Yang F, Wang X, Yao L, Ni Q. Preoperative diagnosis of nonfunctioning pancreatic neuroendocrine tumors. Med Oncol 2011;28:1027-31. [DOI: 10.1007/s12032-010-9611-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
28 Sho S, Court CM, Winograd P, Toste PA, Pisegna JR, Lewis M, Donahue TR, Hines OJ, Reber HA, Dawson DW, Tomlinson JS. A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors. J Gastrointest Surg 2019;23:1392-400. [PMID: 30353489 DOI: 10.1007/s11605-018-4011-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
29 O'Toole D, Delle Fave G, Jensen RT. Gastric and duodenal neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012;26:719-735. [PMID: 23582915 DOI: 10.1016/j.bpg.2013.01.002] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 5.5] [Reference Citation Analysis]
30 Boleslawski E, Dharancy S, Truant S, Pruvot FR. Surgical management of liver metastases from gastrointestinal endocrine tumors. Gastroenterol Clin Biol 2010;34:274-82. [PMID: 20347242 DOI: 10.1016/j.gcb.2010.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
31 House MG, Schulick RD. Endocrine tumors of the pancreas. Curr Opin Oncol. 2006;18:23-29. [PMID: 16357560 DOI: 10.1097/01.cco.0000198974.59239.3c] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
32 Hibi T, Sano T, Sakamoto Y, Takahashi Y, Uemura N, Ojima H, Shimada K, Kosuge T. Surgery for hepatic neuroendocrine tumors: a single institutional experience in Japan. Jpn J Clin Oncol 2007;37:102-7. [PMID: 17234654 DOI: 10.1093/jjco/hyl140] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
33 Strosberg JR, Cheema A, Kvols LK. A Review of Systemic and Liver-Directed Therapies for Metastatic Neuroendocrine Tumors of the Gastroenteropancreatic Tract. Cancer Control 2011;18:127-37. [DOI: 10.1177/107327481101800207] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 4.9] [Reference Citation Analysis]
34 Thiels CA, Bergquist JR, Laan DV, Croome KP, Smoot RL, Nagorney DM, Thompson GB, Kendrick ML, Farnell MB, Truty MJ. Outcomes of Pancreaticoduodenectomy for Pancreatic Neuroendocrine Tumors: Are Combined Procedures Justified? J Gastrointest Surg. 2016;20:891-898. [PMID: 26925796 DOI: 10.1007/s11605-016-3102-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
35 Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, Tseng JF. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer. 2009;115:741-751. [PMID: 19130464 DOI: 10.1002/cncr.24065] [Cited by in Crossref: 201] [Cited by in F6Publishing: 187] [Article Influence: 16.8] [Reference Citation Analysis]
36 Shin JJ, Gorden P, Libutti SK. Insulinoma: pathophysiology, localization and management. Future Oncol. 2010;6:229-237. [PMID: 20146582 DOI: 10.2217/fon.09.165] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 5.2] [Reference Citation Analysis]
37 Demirci E, Kabasakal L, Toklu T, Ocak M, Şahin OE, Alan-Selcuk N, Araman A. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update. Nucl Med Commun 2018;39:789-96. [PMID: 29912750 DOI: 10.1097/MNM.0000000000000874] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 10.7] [Reference Citation Analysis]
38 Berna MJ, Hoffmann KM, Long SH, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore). 2006;85:331-364. [PMID: 17108779 DOI: 10.1097/md.0b013e31802b518c] [Cited by in Crossref: 127] [Cited by in F6Publishing: 49] [Article Influence: 8.5] [Reference Citation Analysis]
39 Ong S, Garcea G, Pollard C, Furness P, Steward W, Rajesh A, Spencer L, Lloyd D, Berry D, Dennison A. A Fuller Understanding of Pancreatic Neuroendocrine Tumours Combined with Aggressive Management Improves Outcome. Pancreatology 2009;9:583-600. [DOI: 10.1159/000212085] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
40 Lee SY, Cheow PC, Teo JY, Ooi LL. Surgical treatment of neuroendocrine liver metastases. Int J Hepatol 2012;2012:146590. [PMID: 22319650 DOI: 10.1155/2012/146590] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
41 Gedaly R, Jeon H, Johnston TD, McHugh PP, Rowland RG, Ranjan D. Surgical treatment of a rare primary renal carcinoid tumor with liver metastasis. World J Surg Oncol 2008;6:41. [PMID: 18430248 DOI: 10.1186/1477-7819-6-41] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
42 Hori T, Takaori K, Uemoto S. Pancreatic neuroendocrine tumor accompanied with multiple liver metastases. World J Hepatol 2014; 6(8): 596-600 [PMID: 25232452 DOI: 10.4254/wjh.v6.i8.596] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
43 Kianmanesh R, O'Toole D, Sauvanet A, Ruszniewski P, Belghiti J. [Surgical treatment of gastric, enteric pancreatic endocrine tumors. Part 2. treatment of hepatic metastases]. J Chir (Paris). 2005;142:208-219. [PMID: 16335893 DOI: 10.1016/s0021-7697(05)80906-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
44 Norton JA. Surgical treatment of neuroendocrine metastases. Best Practice & Research Clinical Gastroenterology 2005;19:577-83. [DOI: 10.1016/j.bpg.2005.04.003] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 4.4] [Reference Citation Analysis]
45 Crosby DA, Donohoe CL, Fitzgerald L, Muldoon C, Hayes B, O'Toole D, Reynolds JV. Gastric neuroendocrine tumours. Dig Surg. 2012;29:331-348. [PMID: 23075625 DOI: 10.1159/000342988] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
46 Strosberg JR, Choi J, Cantor AB, Kvols LK. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control 2006;13:72-8. [PMID: 16508629 DOI: 10.1177/107327480601300110] [Cited by in Crossref: 105] [Cited by in F6Publishing: 89] [Article Influence: 7.0] [Reference Citation Analysis]
47 Kulke M. Advances in the treatment of neuroendocrine tumors. Curr Treat Options in Oncol 2005;6:397-409. [DOI: 10.1007/s11864-005-0043-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
48 Bacchetti S, Bertozzi S, Londero AP, Uzzau A, Pasqual EM. Surgical treatment and survival in patients with liver metastases from neuroendocrine tumors: a meta-analysis of observational studies. Int J Hepatol. 2013;2013:235040. [PMID: 23509630 DOI: 10.1155/2013/235040] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
49 Norton JA, Foster DS, Blumgart LH, Poultsides GA, Visser BC, Fraker DL, Alexander HR, Jensen RT. Incidence and Prognosis of Primary Gastrinomas in the Hepatobiliary Tract. JAMA Surg. 2018;153:e175083. [PMID: 29365025 DOI: 10.1001/jamasurg.2017.5083] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
50 Basuroy R, Srirajaskanthan R, Ramage JK. A multimodal approach to the management of neuroendocrine tumour liver metastases. Int J Hepatol 2012;2012:819193. [PMID: 22518323 DOI: 10.1155/2012/819193] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
51 Nguyen SQ, Angel LP, Divino CM, Schluender S, Warner RR. Surgery in malignant pancreatic neuroendocrine tumors. J Surg Oncol. 2007;96:397-403. [PMID: 17469119 DOI: 10.1002/jso.20824] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 3.4] [Reference Citation Analysis]
52 Ellison EC, Johnson JA. The Zollinger-Ellison syndrome: a comprehensive review of historical, scientific, and clinical considerations. Curr Probl Surg. 2009;46:13-106. [PMID: 19059523 DOI: 10.1067/j.cpsurg.2008.09.001] [Cited by in Crossref: 58] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
53 Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg. 2004;240:757-773. [PMID: 15492556 DOI: 10.1097/01.sla.0000143252.02142.3e] [Cited by in Crossref: 166] [Cited by in F6Publishing: 140] [Article Influence: 9.8] [Reference Citation Analysis]
54 Sartori P, Mussi C, Angelini C, Crippa S, Caprotti R, Uggeri F. Palliative management strategies of advanced gastrointestinal carcinoid neoplasms. Langenbecks Arch Surg 2005;390:391-6. [DOI: 10.1007/s00423-005-0559-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
55 Chorost MI, Catherine Lee M, B. Yeoh C, Molina M, C. Ghosh B. Unknown primary. J Surg Oncol 2004;87:191-203. [DOI: 10.1002/jso.20099] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
56 Kulke MH. Clinical Presentation and Management of Carcinoid Tumors. Hematology/Oncology Clinics of North America 2007;21:433-55. [DOI: 10.1016/j.hoc.2007.04.004] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
57 DeWitt J. EUS for pancreatic endocrine tumors: do we need to know our pancreatic endocrine tumor's DNA? Gastrointest Endosc 2009;69:1081-4. [PMID: 19410041 DOI: 10.1016/j.gie.2008.08.002] [Reference Citation Analysis]
58 Maithel SK, Fong Y. Hepatic ablation for neuroendocrine tumor metastases. J Surg Oncol. 2009;100:635-638. [PMID: 20017158 DOI: 10.1002/jso.21196] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
59 Grobmyer SR, Vogel SB, McGuigan JE, Copeland EM, Hochwald SN. Reoperative surgery in sporadic Zollinger-Ellison Syndrome: longterm results. J Am Coll Surg 2009;208:718-22; discussion 722-4. [PMID: 19476823 DOI: 10.1016/j.jamcollsurg.2008.11.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
60 Wright BE, Lee CC, Bilchik AJ. Hepatic cytoreductive surgery for neuroendocrine cancer. Surg Oncol Clin N Am 2007;16:627-37, ix-x. [PMID: 17606197 DOI: 10.1016/j.soc.2007.04.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
61 Sørbye H, Westre B, Horn A. Curative surgery after neoadjuvant chemotherapy in metastatic poorly differentiated neuroendocrine carcinoma. European Journal of Surgical Oncology (EJSO) 2007;33:1209-10. [DOI: 10.1016/j.ejso.2007.01.030] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
62 Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg 2009;96:175-84. [PMID: 19160361 DOI: 10.1002/bjs.6468] [Cited by in Crossref: 141] [Cited by in F6Publishing: 110] [Article Influence: 11.8] [Reference Citation Analysis]
63 Capurso G, Bettini R, Rinzivillo M, Boninsegna L, Delle Fave G, Falconi M. Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review. Neuroendocrinology. 2011;93:223-229. [PMID: 21358176 DOI: 10.1159/000324770] [Cited by in Crossref: 70] [Cited by in F6Publishing: 58] [Article Influence: 7.0] [Reference Citation Analysis]
64 Price TN, Thompson GB, Lewis JT, Lloyd RV, Young WF. Zollinger-Ellison syndrome due to primary gastrinoma of the extrahepatic biliary tree: three case reports and review of literature. Endocr Pract. 2009;15:737-749. [PMID: 19491075 DOI: 10.4158/ep09022.rar] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
65 Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25:458-511. [PMID: 15180952 DOI: 10.1210/er.2003-0014] [Cited by in Crossref: 401] [Cited by in F6Publishing: 332] [Article Influence: 23.6] [Reference Citation Analysis]
66 Cisco RM, Norton JA. Surgery for gastrinoma. Adv Surg. 2007;41:165-176. [PMID: 17972563 DOI: 10.1016/j.yasu.2007.05.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
67 Ito T, Igarashi H, Uehara H, Berna MJ, Jensen RT. Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore) 2013;92:135-81. [PMID: 23645327 DOI: 10.1097/MD.0b013e3182954af1] [Cited by in Crossref: 111] [Cited by in F6Publishing: 54] [Article Influence: 13.9] [Reference Citation Analysis]
68 Zhang A, Xiang J, Zhang M, Zheng S. Primary Hepatic Carcinoid Tumours: Clinical Features with an Emphasis on Carcinoid Syndrome and Recurrence. J Int Med Res 2008;36:848-59. [DOI: 10.1177/147323000803600428] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
69 Boninsegna L, Panzuto F, Partelli S, Capelli P, Delle Fave G, Bettini R, Pederzoli P, Scarpa A, Falconi M. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur J Cancer. 2012;48:1608-1615. [PMID: 22129889 DOI: 10.1016/j.ejca.2011.10.030] [Cited by in Crossref: 103] [Cited by in F6Publishing: 96] [Article Influence: 10.3] [Reference Citation Analysis]
70 Fisher AT, Titan AL, Foster DS, Worth PJ, Poultsides GA, Visser BC, Dua MM, Norton JA. Management of Ileal Neuroendocrine Tumors with Liver Metastases. J Gastrointest Surg 2020;24:1530-9. [DOI: 10.1007/s11605-019-04309-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
71 Bacchetti S, Pasqual EM, Bertozzi S, Londero AP, Risaliti A. Curative versus palliative surgical resection of liver metastases in patients with neuroendocrine tumors: a meta-analysis of observational studies. Gland Surg. 2014;3:243-251. [PMID: 25493256 DOI: 10.3978/j.issn.2227-684x.2014.02.05] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
72 Clift AK, Frilling A. Management of patients with hepatic metastases from neuroendocrine tumors. Ann Saudi Med. 2014;34:279-290. [PMID: 25811199 DOI: 10.5144/0256-4947.2014.279] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
73 Thakker RV. Multiple Endocrine Neoplasia Type 1. Endocrinology: Adult and Pediatric. Elsevier; 2016. pp. 2566-2593.e9. [DOI: 10.1016/b978-0-323-18907-1.00148-7] [Cited by in Crossref: 5] [Article Influence: 1.0] [Reference Citation Analysis]
74 Krausch M, Raffel A, Anlauf M, Schott M, Lehwald N, Krieg A, Topp SA, Cupisti K, Knoefel WT. “Cherry Picking”, a Multiple Non-anatomic Liver Resection Technique, as a Promising Option for Diffuse Liver Metastases in Patients with Neuroendocrine Tumours. World J Surg 2014;38:392-401. [DOI: 10.1007/s00268-013-2267-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
75 Yamamoto H, Hemmi H, Gu JY, Sekimoto M, Doki Y, Mori M. Minute liver metastases from a rectal carcinoid: A case report and review. World J Gastrointest Surg 2010; 2(3): 89-94 [PMID: 21160856 DOI: 10.4240/wjgs.v2.i3.89] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
76 Nigri G, Petrucciani N, Debs T, Mangogna LM, Crovetto A, Moschetta G, Persechino R, Aurello P, Ramacciato G. Treatment options for PNET liver metastases: a systematic review. World J Surg Oncol. 2018;16:142. [PMID: 30007406 DOI: 10.1186/s12957-018-1446-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
77 Boudreaux JP, Putty B, Frey DJ, Woltering E, Anthony L, Daly I, Ramcharan T, Lopera J, Castaneda W. Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Ann Surg 2005;241:839-45; discussion 845-6. [PMID: 15912033 DOI: 10.1097/01.sla.0000164073.08093.5d] [Cited by in Crossref: 92] [Cited by in F6Publishing: 81] [Article Influence: 5.8] [Reference Citation Analysis]
78 Anthony LB, Strosberg JR, Klimstra DS, Maples WJ, O'Dorisio TM, Warner RR, Wiseman GA, Benson AB, Pommier RF; North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum. Pancreas. 2010;39:767-774. [PMID: 20664474 DOI: 10.1097/mpa.0b013e3181ec1261] [Cited by in Crossref: 160] [Cited by in F6Publishing: 69] [Article Influence: 16.0] [Reference Citation Analysis]
79 Mckenzie S, Lee W, Artinyan A, Mailey B, Pigazzi A, Ellenhorn J, Kim J. Surgical Resection and Multidisciplinary Care for Primary and Metastatic Pancreatic Islet Cell Carcinomas. J Gastrointest Surg 2010;14:1796-803. [DOI: 10.1007/s11605-010-1225-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
80 Strosberg JR, Weber JM, Choi J, Campos TL, Valone TL, Han G, Schell MJ, Kvols LK. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol. 2012;23:2335-2341. [PMID: 22317769 DOI: 10.1093/annonc/mdr614] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
81 Åkerström G, Hellman P, Hessman O, Osmak L. Surgical Treatment of Endocrine Pancreatic Tumours. Neuroendocrinology 2004;80:62-6. [DOI: 10.1159/000080744] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
82 Hofland J, Kaltsas G, de Herder WW. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev. 2020;41. [PMID: 31555796 DOI: 10.1210/endrev/bnz004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 28.0] [Reference Citation Analysis]
83 Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore). 2006;85:295-330. [PMID: 17108778 DOI: 10.1097/01.md.0000236956.74128.76] [Cited by in Crossref: 138] [Cited by in F6Publishing: 108] [Article Influence: 9.2] [Reference Citation Analysis]
84 Blonski WC, Reddy KR, Shaked A, Siegelman E, Metz DC. Liver transplantation for metastatic neuroendocrine tumor: a case report and review of the literature. World J Gastroenterol. 2005;11:7676-7683. [PMID: 16437698 DOI: 10.3748/wjg.v11.i48.7676] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
85 Norton JA, Melcher ML, Gibril F, Jensen RT. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery. 2004;136:1267-1274. [PMID: 15657586 DOI: 10.1016/j.surg.2004.06.057] [Cited by in Crossref: 92] [Cited by in F6Publishing: 71] [Article Influence: 5.8] [Reference Citation Analysis]
86 Kaemmerer D, Prasad V, Daffner W, Hörsch D, Klöppel G, Hommann M, Baum RP. Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol 2009; 15(46): 5867-5870 [PMID: 19998512 DOI: 10.3748/wjg.15.5867] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
87 Gurung B, Hua X, Runske M, Bennett B, LiVolsi V, Roses R, Fraker DA, Metz DC. PTCH 1 staining of pancreatic neuroendocrine tumor (PNET) samples from patients with and without multiple endocrine neoplasia (MEN-1) syndrome reveals a potential therapeutic target. Cancer Biol Ther. 2015;16:219-224. [PMID: 25482929 DOI: 10.4161/15384047.2014.987574] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
88 Dralle H, Krohn SL, Karges W, Boehm BO, Brauckhoff M, Gimm O. Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors. World J Surg 2004;28:1248-60. [PMID: 15517487 DOI: 10.1007/s00268-004-7609-8] [Cited by in Crossref: 81] [Cited by in F6Publishing: 62] [Article Influence: 4.8] [Reference Citation Analysis]
89 Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases. Cancer 2015;121:1172-86. [PMID: 25274401 DOI: 10.1002/cncr.28760] [Cited by in Crossref: 83] [Cited by in F6Publishing: 77] [Article Influence: 11.9] [Reference Citation Analysis]
90 Morgan KA, Adams DB. Solid tumors of the body and tail of the pancreas. Surg Clin North Am. 2010;90:287-307. [PMID: 20362787 DOI: 10.1016/j.suc.2009.12.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
91 Ishida H, Lam AK. Pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification. Critical Reviews in Oncology/Hematology 2020;145:102835. [DOI: 10.1016/j.critrevonc.2019.102835] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
92 Tanno L, Mayo D, Mills S, Takhar A, Cave J, Nolan L, Stedman B, Sundram FX, Abu Hilal M, Connor H, Pearce N, Armstrong T. Proactive multi-modality treatment of Pancreatic Neuroendocrine Tumours (PNETs): Potential survival benefits. Pancreatology 2018;18:304-12. [PMID: 29433805 DOI: 10.1016/j.pan.2017.12.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
93 Butte JM, Montero PH, Solar A, Torres J, Olmos PR, Goñi I, Quintana JC, Martínez J, Llanos O. Cervical metastases of glucagonoma in a patient with multiple endocrine neoplasia type 1: Report of a case. Surg Today 2008;38:1137-43. [DOI: 10.1007/s00595-008-3763-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
94 Madani A, Thomassen I, van Gestel YRBM, van der Bilt JDW, Haak HR, de Hingh IHJT, Lemmens VEPP. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis. Ann Surg Oncol 2017;24:2199-205. [DOI: 10.1245/s10434-016-5734-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
95 Musholt TJ, Lang H. [Indications and operative procedures for neuroendocrine liver metastases]. Chirurg 2009;80:113-21. [PMID: 19212693 DOI: 10.1007/s00104-008-1614-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
96 Barrett JR, Rendell V, Pokrzywa C, Lopez-Aguiar AG, Cannon J, Poultsides GA, Rocha F, Crown A, Beal E, Michael Pawlik T, Fields R, Panni RZ, Smith P, Idrees K, Cho C, Beems M, Maithel S, Weber S, Erik Abbott D. Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit. J Surg Oncol 2020;121:1067-73. [PMID: 32153032 DOI: 10.1002/jso.25896] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
97 Knigge U, Hansen C, Stadil F. Interventional treatment of neuroendocrine liver metastases. The Surgeon 2008;6:232-9. [DOI: 10.1016/s1479-666x(08)80033-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 4] [Article Influence: 2.1] [Reference Citation Analysis]
98 Williams SA. Ehlers RA 2nd, Hunt KK, Yi M, Kuerer HM, Singletary SE, Ross MI, Feig BW, Symmans WF, Meric-Bernstam F. Metastases to the breast from nonbreast solid neoplasms: presentation and determinants of survival. Cancer. 2007;110:731-737. [PMID: 17582626 DOI: 10.1002/cncr.22835] [Cited by in Crossref: 95] [Cited by in F6Publishing: 74] [Article Influence: 6.8] [Reference Citation Analysis]
99 Choi AB, Maxwell JE, Keck KJ, Bellizzi AJ, Dillon JS, OʼDorisio TM, Howe JR. Is Multifocality an Indicator of Aggressive Behavior in Small Bowel Neuroendocrine Tumors? Pancreas 2017;46:1115-20. [PMID: 28902780 DOI: 10.1097/MPA.0000000000000911] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
100 Mayo SC, Herman JM, Cosgrove D, Bhagat N, Kamel I, Geschwind JF, Pawlik TM. Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies. J Am Coll Surg 2013;216:123-34. [PMID: 23063263 DOI: 10.1016/j.jamcollsurg.2012.08.027] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 5.6] [Reference Citation Analysis]
101 Almond L, Hodson J, Ford S, Gourevitch D, Roberts K, Shah T, Isaac J, Desai A. Role of palliative resection of the primary tumour in advanced pancreatic and small intestinal neuroendocrine tumours: A systematic review and meta-analysis. European Journal of Surgical Oncology (EJSO) 2017;43:1808-15. [DOI: 10.1016/j.ejso.2017.05.016] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
102 Rocca A, Calise F, Marino G, Montagnani S, Cinelli M, Amato B, Guerra G. Primary giant hepatic neuroendocrine carcinoma: A case report. International Journal of Surgery 2014;12:S218-21. [DOI: 10.1016/j.ijsu.2014.05.056] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
103 Landen S, Elens M, Vrancken C, Nuytens F, Meert T, Delugeau V. Giant hepatic carcinoid: a rare tumor with a favorable prognosis. Case Rep Surg. 2014;2014:456509. [PMID: 24653852 DOI: 10.1155/2014/456509] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
104 Salem R, Thurston KG. Radioembolization with yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 3: comprehensive literature review and future direction. J Vasc Interv Radiol. 2006;17:1571-1593. [PMID: 17056999 DOI: 10.1097/01.rvi.0000236744.34720.73] [Cited by in Crossref: 151] [Cited by in F6Publishing: 46] [Article Influence: 10.8] [Reference Citation Analysis]
105 Oh TG, Chung MJ, Park JY, Bang SM, Park SW, Chung JB, Song SY. Prognostic factors and characteristics of pancreatic neuroendocrine tumors: single center experience. Yonsei Med J 2012;53:944-51. [PMID: 22869477 DOI: 10.3349/ymj.2012.53.5.944] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
106 Poultsides GA, Huang LC, Chen Y, Visser BC, Pai RK, Jeffrey RB, Park WG, Chen AM, Kunz PL, Fisher GA, Norton JA. Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis. Ann Surg Oncol. 2012;19:2295-2303. [PMID: 22396008 DOI: 10.1245/s10434-012-2305-7] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 5.4] [Reference Citation Analysis]
107 Kianmanesh R, O'toole D, Sauvanet A, Ruszniewski P, Belghiti J. [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors]. J Chir (Paris) 2005;142:132-49. [PMID: 16142076 DOI: 10.1016/s0021-7697(05)80881-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
108 Kimura W, Tezuka K, Hirai I. Surgical management of pancreatic neuroendocrine tumors. Surg Today. 2011;41:1332-1343. [PMID: 21922354 DOI: 10.1007/s00595-011-4547-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
109 Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117:268-275. [PMID: 20824724 DOI: 10.1002/cncr.25425] [Cited by in Crossref: 467] [Cited by in F6Publishing: 398] [Article Influence: 42.5] [Reference Citation Analysis]
110 Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656-4663. [PMID: 19704057 DOI: 10.1200/jco.2009.22.8510] [Cited by in Crossref: 1430] [Cited by in F6Publishing: 631] [Article Influence: 119.2] [Reference Citation Analysis]
111 Maire F, Hammel P, Kianmanesh R, Hentic O, Couvelard A, Rebours V, Zappa M, Raymond E, Sauvanet A, Louvet C, Lévy P, Belghiti J, Ruszniewski P. Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors? Surgery 2009;145:69-75. [PMID: 19081477 DOI: 10.1016/j.surg.2008.08.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
112 Mathur A, Gorden P, Libutti SK. Insulinoma. Surg Clin North Am. 2009;89:1105-1121. [PMID: 19836487 DOI: 10.1016/j.suc.2009.06.009] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 4.8] [Reference Citation Analysis]
113 Norton JA, Foster DS, Ito T, Jensen RT. Gastrinomas: Medical or Surgical Treatment. Endocrinol Metab Clin North Am. 2018;47:577-601. [PMID: 30098717 DOI: 10.1016/j.ecl.2018.04.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
114 Pu N, Habib JR, Bejjani M, Yin H, Nagai M, Chen J, Kinny-Köster B, Chen Q, Zhang J, Yu J, Wu W, Lou W. The effect of primary site, functional status and treatment modality on survival in gastroenteropancreatic neuroendocrine neoplasms with synchronous liver metastasis: a US population-based study. Ann Transl Med 2021;9:329. [PMID: 33708956 DOI: 10.21037/atm-20-5348] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
115 Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008;135:1469-92. [PMID: 18703061 DOI: 10.1053/j.gastro.2008.05.047] [Cited by in Crossref: 479] [Cited by in F6Publishing: 388] [Article Influence: 36.8] [Reference Citation Analysis]
116 Lee L, Ito T, Jensen RT. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies. Expert Rev Anticancer Ther. 2019;19:1029-1050. [PMID: 31738624 DOI: 10.1080/14737140.2019.1693893] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
117 Riff BP, Yang Y, Soulen MC, Pryma DA, Bennett B, Wild D, Nicolas G, Teitelbaum UR, Metz DC. Peptide Receptor Radionuclide Therapy–Induced Hepatotoxicity in Patients With Metastatic Neuroendocrine Tumors. Clinical Nuclear Medicine 2015;40:845-50. [DOI: 10.1097/rlu.0000000000000935] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
118 Wang SC, Fidelman N, Nakakura EK. Management of Well-Differentiated Gastrointestinal Neuroendocrine Tumors Metastatic to the Liver. Seminars in Oncology 2013;40:69-74. [DOI: 10.1053/j.seminoncol.2012.11.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
119 Eriksson J, Stålberg P, Nilsson A, Krause J, Lundberg C, Skogseid B, Granberg D, Eriksson B, Åkerström G, Hellman P. Surgery and Radiofrequency Ablation for Treatment of Liver Metastases from Midgut and Foregut Carcinoids and Endocrine Pancreatic Tumors. World J Surg 2008;32:930-8. [DOI: 10.1007/s00268-008-9510-3] [Cited by in Crossref: 81] [Cited by in F6Publishing: 65] [Article Influence: 6.2] [Reference Citation Analysis]
120 Ahlman H, Nilsson O, Olausson M. Interventional Treatment of the Carcinoid Syndrome. Neuroendocrinology 2004;80:67-73. [DOI: 10.1159/000080745] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
121 Frilling A, Sotiropoulos GC, Li J, Kornasiewicz O, Plöckinger U. Multimodal management of neuroendocrine liver metastases. HPB (Oxford). 2010;12:361-379. [PMID: 20662787 DOI: 10.1111/j.1477-2574.2010.00175.x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 78] [Article Influence: 9.4] [Reference Citation Analysis]
122 Grande E, Díaz Á, López C, Munarriz J, Reina JJ, Vera R, Bernárdez B, Aller J, Capdevila J, Garcia-Carbonero R, Jimenez Fonseca P, Trapero-Bertran M. Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review. Ther Adv Endocrinol Metab 2019;10:2042018819828217. [PMID: 30815246 DOI: 10.1177/2042018819828217] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
123 Norton JA, Harris EJ, Chen Y, Visser BC, Poultsides GA, Kunz PC, Fisher GA, Jensen RT. Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg. 2011;146:724-732. [PMID: 21690450 DOI: 10.1001/archsurg.2011.129] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 6.4] [Reference Citation Analysis]
124 Hodul P, Malafa M, Choi J, Kvols L. The Role of Cytoreductive Hepatic Surgery as an Adjunct to the Management of Metastatic Neuroendocrine Carcinomas. Cancer Control 2017;13:61-71. [DOI: 10.1177/107327480601300109] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
125 Norton JA, Krampitz GW, Poultsides GA, Visser BC, Fraker DL, Alexander HR, Jensen RT. Prospective Evaluation of Results of Reoperation in Zollinger-Ellison Syndrome. Ann Surg. 2018;267:782-788. [PMID: 29517561 DOI: 10.1097/sla.0000000000002122] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
126 Akerström G, Hellman P. Surgical aspects of neuroendocrine tumours. Eur J Cancer 2009;45 Suppl 1:237-50. [PMID: 19775622 DOI: 10.1016/S0959-8049(09)70039-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
127 Plöckinger U, Wiedenmann B. Endocrine tumours of the gastrointestinal tract. Management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol 2005;19:553-76. [PMID: 16183527 DOI: 10.1016/j.bpg.2005.02.013] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
128 Addeo P, Bertin JB, Imperiale A, Averous G, Terrone A, Goichot B, Bachellier P. Outcomes of Simultaneous Resection of Small Bowel Neuroendocrine Tumors with Synchronous Liver Metastases. World J Surg 2020;44:2377-84. [PMID: 32179974 DOI: 10.1007/s00268-020-05467-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
129 Coan KE, Gray RJ, Schlinkert RT, Pockaj BA, Wasif N. Metastatic carcinoid tumors--are we making the cut? Am J Surg 2013;205:642-6. [PMID: 23414634 DOI: 10.1016/j.amjsurg.2012.05.036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
130 Lesurtel M, Nagorney DM, Mazzaferro V, Jensen RT, Poston GJ. When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. HPB (Oxford). 2015;17:17-22. [PMID: 24636662 DOI: 10.1111/hpb.12225] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
131 Kianmanesh R, Sauvanet A, Hentic O, Couvelard A, Lévy P, Vilgrain V, Ruszniewski P, Belghiti J. Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. Ann Surg. 2008;247:659-665. [PMID: 18362629 DOI: 10.1097/sla.0b013e31816a7061] [Cited by in Crossref: 82] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
132 Bertani E, Fazio N, Botteri E, Chiappa A, Falconi M, Grana C, Bodei L, Papis D, Spada F, Bazolli B, Andreoni B. Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: possible indications for a multimodal approach. Surgery 2014;155:607-14. [PMID: 24582492 DOI: 10.1016/j.surg.2013.12.024] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 5.5] [Reference Citation Analysis]
133 Grobmyer SR, Hochwald SN. Reoperative Surgery for the Zollinger-Ellison Syndrome. Advances in Surgery 2010;44:327-46. [DOI: 10.1016/j.yasu.2010.05.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
134 Starke A, Saddig C, Mansfeld L, Koester R, Tschahargane C, Czygan P, Goretzki P. Malignant metastatic insulinoma-postoperative treatment and follow-up. World J Surg. 2005;29:789-793. [PMID: 15880279 DOI: 10.1007/s00268-005-7743-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
135 Salazar R, Villabona C, Fabregat J. [Gastrointestinal and pancreatic neuroendocrine tumors]. Med Clin (Barc) 2006;127:227-31. [PMID: 16938245 DOI: 10.1157/13091016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
136 Hung JS, Chang MC, Lee PH, Tien YW. Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases? World J Surg. 2007;31:2392-2397. [PMID: 17960455 DOI: 10.1007/s00268-007-9264-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
137 de Herder WW, Mazzaferro V, Tavecchio L, Wiedenmann B. Multidisciplinary approach for the treatment of neuroendocrine tumors. Tumori. 2010;96:833-846. [PMID: 21302641 DOI: 10.1177/030089161009600537] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
138 Kaemmerer D, Twrznik M, Kulkarni HR, Hörsch D, Sehner S, Baum RP, Hommann M; Center for Neuroendocrine Tumors, Bad Berka – ENETS Center of Excellence. Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine Neoplasms. Ann Surg 2021;274:e45-53. [PMID: 33030849 DOI: 10.1097/SLA.0000000000003237] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
139 Ruan DT, Warren RS. Palliative techniques for hepatic cancer. Surg Oncol Clin N Am 2004;13:505-16, ix. [PMID: 15236732 DOI: 10.1016/j.soc.2004.04.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
140 Carrasquillo JA, Chen CC. Molecular imaging of neuroendocrine tumors. Semin Oncol. 2010;37:662-679. [PMID: 21167384 DOI: 10.1053/j.seminoncol.2010.10.015] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
141 Folkert IW, Hernandez P, Roses RE. Multidisciplinary management of nonfunctional neuroendocrine tumor of the pancreas. World J Gastroenterol 2016; 22(11): 3105-3116 [PMID: 27003988 DOI: 10.3748/wjg.v22.i11.3105] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
142 Yuan CH, Wang J, Xiu DR, Tao M, Ma ZL, Jiang B, Li ZF, Li L, Wang L, Wang H. Meta-analysis of Liver Resection Versus Nonsurgical Treatments for Pancreatic Neuroendocrine Tumors with Liver Metastases. Ann Surg Oncol. 2016;23:244-249. [PMID: 26111625 DOI: 10.1245/s10434-015-4654-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
143 Fendrich V, Langer P, Celik I, Bartsch DK, Zielke A, Ramaswamy A, Rothmund M. An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg. 2006;244:845-851; discussion 852-853. [PMID: 17122609 DOI: 10.1097/01.sla.0000246951.21252.60] [Cited by in Crossref: 114] [Cited by in F6Publishing: 92] [Article Influence: 8.1] [Reference Citation Analysis]
144 Maxwell JE, Sherman SK, Menda Y, Wang D, O'Dorisio TM, Howe JR. Limitations of somatostatin scintigraphy in primary small bowel neuroendocrine tumors. J Surg Res. 2014;190:548-553. [PMID: 24950794 DOI: 10.1016/j.jss.2014.05.031] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
145 Strosberg J. Neuroendocrine tumours of the small intestine. Best Pract Res Clin Gastroenterol. 2012;26:755-773. [PMID: 23582917 DOI: 10.1016/j.bpg.2012.12.002] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 6.9] [Reference Citation Analysis]
146 Durán HJ, Ielpo B, Díaz E, Fabra I, Caruso R, Malavé L, Cano-Valderrama O, Garcia L, Quijano Y, Vicente E. Predictive prognostic value of local and distant recurrence of F-fluorodeoxyglucose positron emission tomography for pancreatic neuroendocrine tumors with reference to World Health Organization classifications (2004, 2010). Case series study. Int J Surg 2016;29:176-82. [PMID: 27063856 DOI: 10.1016/j.ijsu.2016.03.069] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
147 Tsutsumi K, Ohtsuka T, Mori Y, Fujino M, Yasui T, Aishima S, Takahata S, Nakamura M, Ito T, Tanaka M. Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production. J Gastroenterol. 2012;47:678-685. [PMID: 22350698 DOI: 10.1007/s00535-012-0540-0] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 6.0] [Reference Citation Analysis]
148 Schurr PG, Strate T, Rese K, Kaifi JT, Reichelt U, Petri S, Kleinhans H, Yekebas EF, Izbicki JR. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg. 2007;245:273-281. [PMID: 17245182 DOI: 10.1097/01.sla.0000232556.24258.68] [Cited by in Crossref: 120] [Cited by in F6Publishing: 110] [Article Influence: 8.6] [Reference Citation Analysis]
149 Ito T, Igarashi H, Jensen RT. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol. 2012;47:941-960. [PMID: 22886480 DOI: 10.1007/s00535-012-0642-8] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 7.7] [Reference Citation Analysis]
150 Worhunsky DJ, Krampitz GW, Poullos PD, Visser BC, Kunz PL, Fisher GA, Norton JA, Poultsides GA. Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness. HPB (Oxford). 2014;16:304-311. [PMID: 23991643 DOI: 10.1111/hpb.12139] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
151 Pasqual EM, Bertozzi S, Londero AP, Bacchetti S, Lorenzin D, Pasqualucci A, Moccheggiani F, Federici A, Vivaverlli M, Risaliti A. Long term results of hepatic resection or orthotopic liver transplantation in patients with liver metastases from gastrointestinal neuroendocrine tumors. Oncol Lett 2016;12:3563-70. [PMID: 27900037 DOI: 10.3892/ol.2016.5045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
152 Mittendorf EA, Shifrin AL, Inabnet WB, Libutti SK, Mchenry CR, Demeure MJ. Islet Cell Tumors. Current Problems in Surgery 2006;43:685-765. [DOI: 10.1067/j.cpsurg.2006.07.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
153 Tsvetkova E, Sud S, Aucoin N, Biagi J, Burkes R, Samson B, Brule S, Cripps C, Colwell B, Falkson C, Dorreen M, Goel R, Halwani F, Maroun J, Michaud N, Tehfe M, Thirlwell M, Vickers M, Asmis T. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014. Curr Oncol 2015;22:e305-15. [PMID: 26300681 DOI: 10.3747/co.22.2603] [Reference Citation Analysis]
154 Kiyono Y, Yamashita T, Doi H, Kuge Y, Katsura T, Inui K, Saji H. Is MIBG a substrate of P-glycoprotein? Eur J Nucl Med Mol Imaging 2007;34:448-52. [DOI: 10.1007/s00259-006-0256-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
155 Chouliaras K, Newman NA, Shukla M, Swett KR, Levine EA, Sham J, Mann GN, Shen P. Analysis of recurrence after the resection of pancreatic neuroendocrine tumors. J Surg Oncol 2018;118:416-21. [PMID: 30259518 DOI: 10.1002/jso.25146] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
156 Woodside KJ, Townsend CM, Mark Evers B. Current management of gastrointestinal carcinoid tumors. J Gastrointest Surg. 2004;8:742-756. [PMID: 15358337 DOI: 10.1016/j.gassur.2004.04.010] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]